Exabeam and Inspira Enterprise Announce Strategic Global Partnership to Deliver Intelligent Security Operations at Scale
While this marks the official launch of a global collaboration, the two companies have already achieved regional success in the Middle East, where Inspira was honored in the Exabeam Global Partner Awards as the 2025 Middle East Partner of the Year. That momentum now extends to a global scale, combining cloud-native, self-hosted, and hybrid security operations from Exabeam with Inspira's intelligent, industry-aligned security services.
Bringing AI-Powered, Industry-Tailored SOC Services to the World
Inspira delivers adaptive, intelligent, and customer-centric cybersecurity solutions for the resilient businesses of tomorrow. Their comprehensive services span advisory, transformation, and operations, tailored to high-risk and regulated sectors including healthcare, BFSI, education, and government.
The partnership integrates advanced behavioral analytics and risk-scoring capabilities from Exabeam with Inspira's industry-aligned SOC model. Through its state-of-the-art Cyber Fusion Centers, including a flagship facility in Dallas, Inspira offers 24x7 threat monitoring, detection, and response. Its iSMART² dashboard further empowers organizations with real-time visibility, advanced analytics, and actionable intelligence across IT, cloud, OT, and third-party ecosystems.
'Inspira brings exactly what today's organizations need in a security partner — deep industry expertise, global reach, and a modern, AI-driven approach to cybersecurity operations,' said Craig Patterson, Global Channel Chief at Exabeam. 'Through this partnership, we're making it easier for enterprises around the world to adopt market-leading security solutions from Exabeam in a way that's flexible, scalable, and aligned to real business needs.'
'Our partnership with Exabeam enables us to deliver truly intelligent, AI-driven cybersecurity that's tailored to the unique needs of each industry and region we serve,' said Amit Gandre, CEO of Americas at Inspira Enterprise. 'By combining leading behavior analytics and security operations platforms from Exabeam with our global Cyber Fusion Centers and deep expertise in sectors like BFSI, healthcare, and government, we're empowering organizations to build resilient, business-aligned security operations that can detect and respond to threats faster and more effectively.'
To learn more about Exabeam and Inspira, visit www.exabeam.com
About Exabeam
Exabeam is a leader in intelligence and automation that powers security operations for the world's smartest companies. As a global cybersecurity innovator, Exabeam provides industry-proven, security-focused, and flexible solutions for faster, more accurate threat detection, investigation, and response (TDIR). Cutting-edge technology enhances security operations center performance, optimizing workflows and accelerating time to resolution. With consistent leadership in AI innovation and a proven track record in security information and event management (SIEM) and user behavior analytics, Exabeam empowers global security teams to combat cyberthreats, mitigate risk, and streamline operations.
Learn more at www.exabeam.com
About Inspira Enterprise
Inspira Enterprise is a global Cybersecurity, Data Analytics, and Artificial Intelligence services provider with a presence in North America, ASEAN, the Middle East, Africa, and India. We deliver adaptive, intelligent, and customer-centric solutions to various industries, including Banking, Financial Services, and Insurance (BFSI), Healthcare, Public Sector, Manufacturing, Education, Oil & Gas and Utilities.
Our expertise in AI-driven cybersecurity enables comprehensive protection against evolving cyber threats to help protect your enterprise. We leverage advanced analytics and AI-powered threat detection to offer real-time visibility and proactive risk management, strengthening organizational security. At the core of our offerings is iSMART2—an advanced AI-driven platform delivering continuous monitoring, analytics, and actionable insights to mitigate risks and stay ahead of emerging threats.
With 1600+ professionals, we've successfully delivered complex transformation projects for 550+ clients. Our AI and cybersecurity capabilities empower businesses to build resilient, future-ready digital ecosystems. Learn more: www.inspiraenterprise.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11-06-2025
- Yahoo
Inspira's ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions
RA'ANANA, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that its FDA-cleared ART100 system adoption has begun to positively impact commercialization interest and efforts, representing a key milestone and significantly contributes to the Company's commercial validation. The ART100 system has been successfully integrated into real-world clinical workflows at leading tier-one U.S. hospitals over the past several months. Details of specific hospital deployments are subject to confidentiality, but reflect Tier-1 facilities in the U.S. This clinical use reflects growing confidence in the system's potential to support patients in critical condition and positions Inspira at the forefront of a rapidly evolving market of life-saving technologies. The consistent use of the ART100 has prompted a wave of interest from additional U.S. and international healthcare institutions, as well as governmental authorities. The Company is currently engaged in commercial discussions with various stakeholders across multiple regions and is scaling up operational capabilities to support the anticipated adoption of the ART100. "Over the past several months, the ART100 has been used in real-world settings at leading U.S. hospitals, supporting patients. This clinical use sends a strong message to the global market – that our technology is trusted by physicians, integrated into workflows, and is now driving commercial demand."— Dagi Ben-Noon, CEO, Inspira Technologies This announcement builds on Inspira's global rollout strategy, expanded manufacturing capacity and advanced negotiations with a European government authority. The Company anticipates announcing additional strategic deployments and commercial milestones in the near term. About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that the adoption of the ART100 has begun to positively impact commercialization interest and efforts, representing a key milestone and which it believes significantly contributes to its commercial validation, the belief that this clinical use reflects growing confidence in the ART100's potential to support patients in critical condition and positions the Company at the forefront of a rapidly evolving market of life-saving technologies, that the consistent use of the ART100 has prompted a wave of interest from additional U.S. and international healthcare institutions, as well as governmental authorities, that it is currently engaged in commercial discussions with various stakeholders across multiple regions and is scaling up operational capabilities to support the anticipated adoption of the ART100 and the belief that the clinical use of the ART100 sends a strong message to the global market – that the Company's technology is trusted by physicians, integrated into workflows, and is now potentially driving commercial demand.. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at Company ContactInspira Technologies – Media RelationsEmail: info@ +972-9-9664485Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
06-06-2025
- Yahoo
Inspira Technologies scales up ART100 production capabilities
Inspira Technologies (IINN) has scaled-up its production capabilities for its U.S. Food and Drug Administration-cleared INSPIRA ART100 system, in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations. Inspira has ramped up strategic production in order to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on IINN: Disclaimer & DisclosureReport an Issue Inspira Technologies initiated with a Buy at Litchfield Hills Inspira Technologies Announces Shareholder Meeting to Address Nasdaq Compliance Inspira Technologies Launches Global Rollout of ART100 System Inspira initiates global commercial rollout of ART100 system Inspira Technologies Restructures Executive Team for Strategic Alignment Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-06-2025
- Yahoo
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the 'ART100 system'), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations. this ramp up strategic production aims to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs. 'We are preparing for commercial execution,' said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. 'Our dialogue with a European government body has advanced to a stage where operational readiness is essential. Expanding our production capacity will enable us to meet projected deployment needs quickly and efficiently.' This move follows Inspira's recent announcement of its global rollout strategy and reflects the Company's commitment to fast-track revenue generation from the ART100 system, while continuing its development of its next-generation platforms, the ART500 and the HYLA™ blood sensor. The Company believes the current momentum—combined with a growing global focus on scalable respiratory solutions—may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the critical care and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it expects demand for its ART100 system from a European governmental authority, that it has ramped up its production in order to meet expected near term delivery needs, , the benefits and advantages of the ART100, that the ART100 system is gaining traction as a reliable device for a critical care and emergency preparedness programs, the potential outcome of its procurement negotiations with a European government authority, its belief that expanding its production capacity enables the Company to meet projected deployment needs quickly and efficiently, and its belief that current momentum may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at Company ContactInspira Technologies – Media RelationsEmail: info@ +972-9-9664485Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
